$NBIO - This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors.
https://finance.yahoo.com/news/nascent-prepar...00620.html